Background. Cardiovascular disease (CVD) among HIV-infected individuals contributes significantly to morbidity and mortality, accounting for one third of non-AIDS defining illness and 11% of deaths. Compared with the general population, HIVinfected individuals are known to have elevated risk for CVD with chronic infection, regardless of HIV RNA levels and studies suggests that clinicians are not appropriately managing ASCVD risk in HIV-infected patients.
Background. The fibroblast growth factor (FGF) 23 is a hormone-like molecule that secretes from osteoblasts and has the function of suppressing the reabsorption of phosphorus in the distal renal tubule and lowering serum phosphorus. It has been shown that renal dysfunction increases serum FGF23 levels. Although the mechanism remains to be determined, it is also reported that the elevation of serum FGF23 might increase the risk of coronary vascular diseases (CVD). Nevertheless, there are very few reports related to FGF23 in patients with HIV. The goal of the present study was to investigate the relationship between serum FGF23 levels and clinical factors HIV patients.
Methods. Male HIV patients who visited the outpatient clinic of Teikyo University Hospital, Tokyo, Japan in 2015 and had been treated with anti-retroviral therapy for more than six months were enrolled. In addition to serum FGF23, clinical factors were also collected, including age, ART regimens, and laboratory data, and Framingham Coronary Heart Disease Risk Score (FHS). To study correlations with FGF23, spearman coefficients was used. To identify factors independently related with FGF23, multiple regression analysis was used.
Results. Sixty-seven patients were enrolled. The median age was 43.7 years old. Median CD4 cell counts was 529/μL, and the median serum FGF 23 level was 36.0 pg/mL. According to spearman coefficients, serum FGF23 levels correlated with HIV RNA > 50 copies (r = 0.3911, P = 0.0011), serum cystatin C level (r = 0.3199, P = 0.0097), and some specific anti-HIV drugs; abacavir (ABC)/lamivudine (3TC) use (r = 0.3345, P = 0.0057). FHS was not correlated (P = 0.9655). According to multiple regression analysis, ABC/3TC use (P = 0.00990) and HIV RNA >50 copies (P = 0.00002) were significant factors related with the increase of serum FGF23 levels.
Conclusion. Poor virological control and ABC/3TC use were significant factors that elevated serum FGF23 levels. Considering that ABC/3TC is a well-known factor in the increase of the risk of CVD, FGF23 might be one of the factors that increases the risk of CVD in HIV patients receiving ABC/3TC, though FGF23 was not significantly related with FHS in our all study patients.
Disclosures. Background. Racial and ethnic minorities comprise an increasing proportion of the US population, and are disproportionately affected by HIV. Dyslipidemia is a key comorbidity in HIV due to high prevalence and demonstrated racial disparities in testing and treatment among non-HIV patients. Previous analysis has showed that HIVpositive African American (AA) patients were less likely to have had a lipid profile done and less likely to have been diagnosed with dyslipidemia than other racial groups.
Methods. Electronic medical records (EMR) identified 1,457 HIV patients from the HIV clinic at Henry Ford Hospital, Detroit, Michigan from March 2013 to November 2015. Race/ethnicity and gender were identified by self-report and then a retrospective EMR review of patients tested for, and documented ICD-9 codes for dyslipidemia was done. Descriptive analyses and group comparisons were performed between AA and other racial/ethnic groups.
Results. 1,220 HIV patients had lipid levels tested with 25.7% having dyslipidemia after HIV diagnosis. Among those, it was found that lipid abnormalities varied by race; on average, Hispanics, had lower total cholesterol (P = 0.040), AA patients had lower triglycerides (P < 0.001), and White patients had higher triglycerides (P > 0.001). HDL levels were higher in AA patients and lowest in White patients (P < 0.001), while Hispanics had lower LDL values (P-value 0.009). There was no statistically significant (P = 0.519) difference between the lipid lowering drug (LLD) group prescribed by race, and the type of dyslipidemia was the primary predictor of LLD provided to the patients (P < 0.001). Patients prescribed fibrates were statistically more likely to have met their ATP III treatment goals at 1 year as compared with statins, regardless of race (P = 0.005). The odds of meeting treatment goals were 54% (OR 0.46, CI 0.26-0.71) less among AA patients regardless of medication.
Conclusion. Dyslipidemia is prevalent in our HIV population. Racial differences in testing, lipid abnormalities and treatment outcomes among these vulnerable HIV minorities necessitate further investigation to close the gaps in care and improve our management of dyslipidemia for our HIV patients.
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